Teva shocks skeptics with stock rebound
New CEO and successful patient outreach drove Israeli drug giant's shares to three-year high.
A recent jump in Teva Pharmaceutical Industries’ stock price surprised many analysts, who have grown pessimistic about the performance of the Israel-based drug manufacturer.
register with haaretz
Like us on Facebook and get articles directly in your news feed